

Vanessa Desantis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8110909/publications.pdf>

Version: 2024-02-01

29
papers

908
citations

566801

15
h-index

552369

26
g-index

32
all docs

32
docs citations

32
times ranked

1497
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiangiogenic drugs as chemosensitizers in hematological tumors. , 2022, , 111-125.		0
2	Myeloma cells regulate <scp>miRNA</scp> transfer from fibroblastâ€derived exosomes by expression of <scp>lncRNAs</scp>. Journal of Pathology, 2022, 256, 402-413.	2.1	15
3	The Landscape of lncRNAs in Multiple Myeloma: Implications in the â€œHallmarks of Cancerâ€; Clinical Perspectives and Therapeutic Opportunities. Cancers, 2022, 14, 1963.	1.7	9
4	The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. Journal of Clinical Medicine, 2022, 11, 2513.	1.0	15
5	A Challenging Case of Visceral Leishmaniasis. Reports, 2022, 5, 23.	0.2	3
6	Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma. American Journal of Pathology, 2021, 191, 748-758.	1.9	9
7	MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease. Cancers, 2021, 13, 3650.	1.7	13
8	Diabetes and Alzheimerâ€™s Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?. Antioxidants, 2021, 10, 1257.	2.2	29
9	P-078: Prognostic value of immune cells in the multiple myeloma bone marrow microenvironment: a meta-analysis within silico and in vitro validation. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S81-S82.	0.2	0
10	Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression. Cells, 2021, 10, 3185.	1.8	16
11	MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance. International Journal of Molecular Sciences, 2020, 21, 3084.	1.8	42
12	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradationâ€Induced Mitochondrial Oxidative Stress. Cancer Research, 2020, 80, 2340-2354.	0.4	41
13	Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells, 2020, 9, 167.	1.8	68
14	High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. Journal of Clinical Medicine, 2019, 8, 997.	1.0	45
15	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myelomaâ€Enhanced Angiogenesis: A Novel Therapeutic Target?. Neoplasia, 2019, 21, 93-105.	2.3	28
16	Bone marrow fibroblasts overexpress miRâ€27b and miRâ€214 in step with multiple myeloma progression, dependent on tumour cellâ€derived exosomes. Journal of Pathology, 2019, 247, 241-253.	2.1	74
17	Abstract C052: FGF trapping impairs multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress. , 2019, , .		0
18	JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia, 2018, 32, 736-743.	3.3	55

#	ARTICLE	IF	CITATIONS
19	The role of SIRT6 in tumors. <i>Haematologica</i> , 2018, 103, 1-4.	1.7	39
20	Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma. <i>Annals of Hematology</i> , 2018, 97, 1251-1258.	0.8	13
21	Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin [®] protein MP0250: a preclinical study. <i>Oncotarget</i> , 2018, 9, 13366-13381.	0.8	37
22	Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 1926-1935.	0.8	14
23	Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma. <i>Translational Oncology</i> , 2018, 11, 1350-1357.	1.7	56
24	Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 20563-20577.	0.8	45
25	Abstract B134: Inhibition of the fibroblast growth factor system by a new FGF trap induces oxidative stress and mitochondrial apoptosis in multiple myeloma cells. , 2018, , .		0
26	Isolation and characterization of neural stem cells from dystrophic mdx mouse. <i>Experimental Cell Research</i> , 2016, 343, 190-207.	1.2	12
27	Halting pro-survival autophagy by TGF β 2 inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. <i>Leukemia</i> , 2016, 30, 640-648.	3.3	69
28	Microenvironment drug resistance in multiple myeloma: emerging new players. <i>Oncotarget</i> , 2016, 7, 60698-60711.	0.8	137
29	Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells <i>in vitro</i> . <i>European Journal of Haematology</i> , 2015, 95, 65-74.	1.1	17